ClinicalTrials.gg

Program

BI 3031185

A development code.

Its studies are mostly in Borderline Personality Disorder, led by Boehringer Ingelheim.

Furthest: phase 1, since Feb 5, 20245 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim50 open or runningphase 1since Feb 5, 2024Feb 5, 2024none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 5, 2024First study: phase 1 study in HealthyFirst studyNCT06255340 · 75 enrolled · Germany
  2. Mar 27, 2025Phase 1 study in HealthyNCT06916702 · 100 enrolled · Germany
  3. Jun 2, 2025Phase 1 study in Borderline Personality DisorderNCT07001475 · 78 enrolled · Germany
  4. Oct 2, 2025Phase 1 study in HealthyNCT07211425 · 14 enrolled · Germany
  5. Jun 15, 2026Phase 1 study in HealthyNCT07656792 · 8 enrolled · Japan

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07656792Healthy · Japan1TerminatedSep 23, 20268
NCT07211425Healthy · Germany1CompletedJan 21, 202614
NCT07001475Borderline Personality Disorder · Germany1CompletedAug 6, 202678
NCT06916702Healthy · Germany1SuspendedSep 23, 2026100
NCT06255340Healthy · Germany1CompletedAug 28, 202475

How it is read

Names in the registry

  • “BI 3031185”, 5 entries

Codes read as this program: BI3031185.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.